Cai X, et al. - Weight changes in patients who received different dosages of sodium glucose cotransporter 2 (SGLT2) inhibitors were evaluated in this meta-analysis. In patients with type 2 diabetes who received different dosages of SGLT2 inhibitors, body weight significantly decreased compared with patients who received a placebo. Furthermore, there was a statistically significant dosage-dependent trend in body weight reduction in patients treated with dapagliflozin.